The Fluorescence Applications in Biotechnology and Life Sciences Network and Science Industry Australia Inc invite you to a seminar on

“Clinical Applications of Proteomics”
Professor Ian Smith, Deputy Dean Research, Faculty of Medicine Nursing and Health Sciences, Monash University

“Biomarker Discovery and Detection”
Assoc. Professor Ed Nice, Head, Protein Biosensing Group, The Ludwig Institute

“Investing in a Cooperative Research Centre”
Mr David Tayler, BDM, FABLS Network

When: Thursday 13th December 2007, 4.00 – 6.00pm
Where: Bio21 Institute Auditorium, The University of Melbourne
30 Flemington Road (near cnr Park Dve), Parkville - www.bio21.org/about-
Parking: No public parking is available on site at Bio21. Limited street and meter parking is available in the surrounding streets.

RSVP by 10 Dec:
David Tayler, FABLS, Ph: 02 9850 9078, Email: dtayler@ics.mq.edu.au
Pam Damby, SIA, Ph: 03 9824 5488, Email: siav@scienceindustry.com.au

This is a free event. All welcome.

Ian Smith
Ian Smith is a Professorial Fellow in the Department of Biochemistry & Molecular Biology at Monash University and founding Director of Biomedical Proteomics at Monash University. He is the Deputy Dean Research for the Faculty of Medicine Nursing and Health Sciences.

His research applies proteomics technologies to study the proteases involved in the generation and metabolism of peptide regulators of both brain and cardiovascular function. His research is well-recognised internationally, is invited to speak at international meetings. Ian serves on many editorial boards and has published over 180 peer reviewed research papers.

Ian consults widely with pharmaceutical and biotechnology companies and has filed seven patents. He is a co-founder of the proteomics-based, listed company, Cryptome Research Pty Ltd. (now Healthlinx Pty Ltd), and is a non-executive director of Auspep Pty Ltd. Ian is the deputy chairman of the NH&MRC project grant committee and a member of Lorne Protein committee and is a founding member of the HUPO (HUman Proteomic Organisation) cardiovascular medicine initiative.
Ian’s presentation will focus on clinical applications of proteomics, the development of new diagnostics and prognostics and will illustrate his talk with examples of research work coming out of his laboratory at Monash University.

**Ed Nice**
Associate Professor Ed Nice is a Principal Research Fellow and Associate Member at The Ludwig Institute for Cancer Research where he is Head of the Protein Biosensing Group. His major scientific interests are in the development of techniques for the micropurification of proteins and peptides, biosensor analysis of protein-protein interactions, the development of novel biomarker assays and proteomics. Ed has applied these techniques to an understanding of signaling pathways related to cancer and to developing highly sensitive methods for protein and peptide microanalysis. Ed is currently working on the use of affinity-based biosensors as micropurification platforms for proteomic analysis of protein signalling complexes, the potential of faecal proteomics to identify potential colon cancer biomarkers and the development of sensitive and specific biosensor assays for the detection of telomerase in clinical samples. He has published over 160 peer reviewed papers, and is a consultant for several biotech companies.

Ed will overview emerging technologies with potential in the area of biomarker research. He will illustrate these with examples from his own laboratory and from the recent literature.

**Cooperative Research Centre**
As an example of potential investment in a $100 million CRC to be established in 2008 and which is tentatively named CRC for Advanced Cell Technologies. It will focus on the development of precision instrumentation, reagents and software to expand the boundaries in diagnostics, and the treatment of disease by specialising in:

- Real time multiplex detection of pathogens in a health care setting developing approaches for rapid detection of a range of harmful microorganisms
- Purification of cell populations developing approaches for efficient purification of important cell populations such as adult stem cells
- Cellular Biosensors developing novel cellular assays based on the use of genetically encoded fluorescent probes.

Companies are invited to nominate research priorities. Twenty leading researchers from 6 Australian universities and 2 government departments are cooperating.

**David Tayler**
David is the Business Development Manager for the network, *Fluorescence Applications in Biotechnology and Life Sciences*, based at Macquarie University. He is a member of a founding group of scientists establishing a new Cooperative Research Centre for Advanced Cell Technologies. With 20 years experience in research management and commercialisation, David has managed a private enterprise R&D company, which successfully completed more than 300 projects for all levels of government and private industry in a wide range of industries.

**FABLS**
The ARC Network for *Fluorescence Applications in Biotechnology and Life Sciences* (FABLS) inspires and coordinates research programs relating to applications of fluorescence that require a high degree of interaction between biology, physics, and chemistry. The network comprises 365 researchers and company representatives with a common interest in the tools of fluorescence, lasers, confocal microscopes and fluorescent reagents, as it applies to genomics, proteomics, bioengineering, medical diagnostics, and industrial microbiology.

**SIA**
Science Industry Australia is the national industry association which represents the professional science industry, and our members include scientific and life science product and equipment suppliers; scientific, analytical and diagnostic equipment manufacturers, exporters and importers; chemical and gas companies; software companies and specialised recruiters.